Sign in
Taking people in United StatesPhase 3

BHV-1300 compared with placebo for adults with overactive thyroid from Graves' disease

Tests BHV-1300 in adults with Graves' disease who have an overactive thyroid.

Key facts

Who runs it
Biohaven Therapeutics Ltd.
Where
Albuquerque, Amarillo, Asheville, Atlanta, Baton Rouge, Burbank, Canton, Champaign, Chattanooga, Cincinnati, Dallas, Denton, Doral, El Paso, Farmington Hills, Fayetteville, Fort Myers, Greenville, Hialeah, Hollywood, Houston, Huntington Beach, Kansas City, La Jolla, Las Vegas, Layton, Lenexa, McKinney, Memphis, Miami, Midlothian, Morehead City, Norman, North Charleston, Oak Brook, Oakland, Orchard Park, Palm Beach Gardens, Philadelphia, Raleigh, San Antonio, San Diego, Seattle, Shavano Park, South Gate, Springfield, St Louis, Statesville, Tampa, Tucson, Walnut Creek, Washington D.C., Weslaco, and Wilmington, United StatesSee the 57 sitesAlso in 2 other countries, 6 sites
Registry title
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Status
Recruiting
Phase
Phase 3
People taking part
300 people, planned
Started
26 Jun 2026
Expected to end
Feb 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BHV-1300
  • Placebo
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease who currently have an overactive thyroid (hyperthyroidism).

Age
18 Years to 70 Years
Sex
All sexes can join.
Disease stage
Active hyperthyroidism caused by Graves' disease.
Earlier treatment
People who had radioactive iodine or thyroid surgery cannot join. People who took levothyroxine, desiccated thyroid extract or T3 within six weeks of the Baseline/Day 1 Visit cannot join.
Biomarker or test result
Graves' disease confirmed by a blood test showing raised autoantibodies.

Main reasons for not taking part

  • Overactive thyroid from another cause, such as toxic adenoma or toxic multinodular goiter
  • Thyroid storm (a severe, life-threatening thyroid flare) within 6 weeks of Screening
  • Another autoimmune disease that needs treatment
  • Moderate to severe thyroid eye disease (TED), or planned surgery, radiation or medical treatment for TED
  • Expected need for urgent thyroid surgery or ablation within six weeks of Baseline/Day 1 or during the study

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Participants must have serologically confirmed Graves' disease as documented by presence of elevated autoantibodies
  • Participants must have active hyperthyroidism due to Graves' disease

Who cannot take part

  • History of treatment with radioactive iodine or thyroid surgery
  • Have received levothyroxine, desiccated thyroid extract, or T3 at any dose within six weeks of the Baseline/Day 1 Visit
  • Are expected to require urgent or emergent thyroid surgery or ablation within six weeks of Baseline/Day 1 or throughout the study
  • History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter)
  • Thyroid storm, i.e. severe thyrotoxicosis with evidence of systemic decompensation (e.g., Burch-Wartkofsky Point Scale of ≥ 45 or Japanese Thyroid Association category 1 or 2, with accompanying manifestations including hyperpyrexia, tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor, and coma, as well as nausea, vomiting, diarrhea, or hepatic failure) within 6 weeks of Screening
  • Have autoimmune disease other than Graves' disease requiring treatment
  • Have moderate to severe thyroid eye disease (TED) or are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

Also in 2 other countries, 6 sites

  • Albuquerque, New MexicoHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Amarillo, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Asheville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Atlanta, GeorgiaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Baton Rouge, LouisianaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Burbank, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Canton, OhioHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Champaign, IllinoisHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Chattanooga, TennesseeHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Cincinnati, OhioHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Dallas, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Dallas, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Denton, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Doral, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • El Paso, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Farmington Hills, MichiganHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Fayetteville, GeorgiaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Fort Myers, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Greenville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Hialeah, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Hollywood, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Huntington Beach, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Kansas City, MissouriHospital not named in the registryContact: Chief Medical OfficerTaking people
  • La Jolla, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Las Vegas, NevadaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Layton, UtahHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Lenexa, KansasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • McKinney, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Memphis, TennesseeHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Miami, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Midlothian, VirginiaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Morehead City, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Morehead City, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Norman, OklahomaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • North Charleston, South CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Oak Brook, IllinoisHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Oakland, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Orchard Park, New YorkHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Palm Beach Gardens, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Raleigh, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • San Antonio, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • San Diego, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Seattle, WashingtonHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Shavano Park, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • South Gate, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Springfield, IllinoisHospital not named in the registryContact: Chief Medical OfficerTaking people
  • St Louis, MissouriHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Statesville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Tampa, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Tucson, ArizonaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Walnut Creek, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Washington D.C., District of ColumbiaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Weslaco, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Wilmington, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

The 2 groups in the trial

  • BHV-1300Treatment being tested

    BHV-1300 is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.

  • PlaceboPlacebo, for comparison

    Matching placebo is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease
Plain-language title
BHV-1300 compared with placebo for adults with overactive thyroid from Graves' diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07661056, who can take part
Record updated
12 November 2026